Study on LY2880070 and Gemcitabine for Treating Ewing Sarcoma, Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Inclusion Criteria

• Patients and/or their guardians must provide written consent to participate.
• Patients must weigh at least 40 kg and can be of any age.
• Must have a confirmed diagnosis of advanced or metastatic Ewing sarcoma or Ewing-like sarcoma, verified by specific genetic markers.
• Must be able to swallow capsules.
• The cancer must have not responded to standard chemotherapy treatments.
• Must have measurable disease according to specific medical criteria.
• Must have a performance status score of 70% or higher, indicating they are able to care for themselves with some assistance.
• Must have completed previous cancer treatments and recovered from any side effects.
• Must meet specific organ function requirements, including:
  • Adequate blood cell counts and kidney, liver, and heart function.
• Women of childbearing potential must have a negative pregnancy test and agree to use contraception during and after the study.
• Men and women of reproductive potential must agree to use contraception during and after the study.

Exclusion Criteria

• Patients for whom gemcitabine is not suitable.
• Patients with uncontrolled infections.
• Patients with symptomatic brain metastases or those requiring steroids for brain metastases.
• Patients who are pregnant or breastfeeding.
• Patients with certain heart conditions or a family history of heart rhythm problems.
• Patients who may not be able to follow the study's safety monitoring requirements.
• Patients with known allergies to gemcitabine.